Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI:10.1080/14796694.2024.2368450

Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yang, Yvette Le Lorier, Boris Gorsh, James Signorovitch

{"title":"Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM.","authors":"Lucia Masarova, Srdan Verstovsek, Tom Liu, Sumati Rao, Gautam Sajeev, Mirko Fillbrunn, Ryan Simpson, Weilong Li, Joseph Yang, Yvette Le Lorier, Boris Gorsh, James Signorovitch","doi":"10.1080/14796694.2024.2368450","DOIUrl":null,"url":null,"abstract":"Aim: To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol.Methods: Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies.Results: Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person).Conclusion: Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508939/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2368450","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol.Methods: Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies.Results: Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person).Conclusion: Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.

查看原文本刊更多论文

来自 MOMENTUM 的莫美洛替尼与达那唑治疗骨髓纤维化患者的输血相关成本抵消和时间负担。

目的：与达那唑相比，估算骨髓纤维化和贫血患者接受莫美洛替尼治疗的预计美国成本和时间负担。方法：根据患者的输血情况计算成本和时间负担：根据 MOMENTUM 试验中患者的输血情况以及从以往研究中提取的估算值计算成本和时间负担。结果预计与达那唑相比，莫美洛替尼减少输血可为输血依赖型和输血依赖/需要输血的骨髓纤维化患者分别节省成本和时间：每人每年医疗成本（53143美元和46455美元）、门诊输血成本（42021美元和8370美元）以及每人每年节省时间（173小时和35小时）。结论预计与达那唑相比，使用莫美洛替尼治疗骨髓纤维化和贫血患者可减少输血次数，从而节约成本和时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.